45-fda-rebuttles-and-adwork

Valuation

Generous asset valuation: $5,000,000,000. The listed price is the platform maximum; acquisition at valuation is handled by direct enquiry.

FDA / FTC Compliance Checklist — Execution Items

FDA / FTC Compliance Checklist — Execution Items

> Why this file exists. The six per-project FDA_REBUTTAL.md memos argue a

> defensible position. But that position only holds if it is executed — a

> rebuttal is worthless if a single "cure" file survives into public view, or a

> supplement ships with an ineligible ingredient. This is the cross-cutting,

> non-negotiable checklist that backs every rebuttal. **Not legal advice — an FDA

> regulatory attorney must sign off before anything goes public or on sale.**

A. The "cure" scrub (applies to 10, 11, 12, 13, 33)

The word "cure" is the single largest liability across the catalog. Removing it from

the marketing surface alone is not enough — discovery reveals internal naming.

• [ ] Rename public product titles, SKUs, URL keys, and meta fields — no "cure,"

"treat," "prevent," "recovery."

• [ ] Rename the 300 NNN-Disease-CURE.md files (Project 13) → …-Mechanism-Analysis.md.
• [ ] Scrub "CURE" from generator scripts, templates, index files, and **archives/

backups** — one surviving *-CURE.md undermines the repositioning.

• [ ] Update or archive internal folder names (10-diabetes-cure-discovery, etc.);

these are discoverable and support an "intent" argument if left as-is.

• [ ] Confirm 100% completion with a repo-wide search for cure/Cure/CURE

before any public release.

B. NeuroElement ingredient eligibility — a GATE, not a task (Project 22, inherited by 33)

• [ ] Confirm every one of the 7 compounds is a lawful dietary ingredient

(pre-DSHEA / NDIN / GRAS / ODSL-listed) in writing before any sale.

• [ ] Ebselen — synthetic organoselenium, not an established US supplement

ingredient. Either obtain eligibility confirmation or use the documented

reformulation path that drops it. Until then, NeuroElement **cannot lawfully be

marketed as a dietary supplement** (selling first risks an unapproved-new-drug

violation, FDCA § 505).

• [ ] NAC — contested status (drug approved 1963; 2020–21 warning letters; 2022

informal enforcement discretion that can be withdrawn). Treat as at-risk;

monitor FDA guidance.

C. Supplement labeling discipline (Project 22 + OTC vitamins in 33)

• [ ] Consumer claims limited to structure/function ("supports memory, focus,

brain energy"). No disease names, no "coverage %," no "clinically proven."

• [ ] FDA disclaimer on label and page: *"not evaluated by the FDA; not intended to

diagnose, treat, cure, or prevent any disease."*

• [ ] File the structure/function claim notification with FDA within 30 days of

marketing (informational only — it is not FDA approval).

• [ ] Keep the "designed against 54 diseases / 89% coverage" figures internal;

confirm they do not appear in the consumer page hero or the patent specification

in a way that reads as a disease claim.

D. Register separation (Projects 22, 33)

• [ ] Clinical/therapeutic language (MJFF outreach, patent specification) and

consumer structure/function language are kept in separate registers.

• [ ] Any outreach to patient organizations is reviewed by counsel first — it is

discoverable and can be used to infer "intended use."

E. Bundle structure (Project 33)

• [ ] Make the wall between disease research and ingestibles structural: separate

SKUs and packaging, not just a clause in a license. Disease research must never

ship in the same box as a supplement.

• [ ] Rename "Health Recovery" → a portfolio-oriented title with no recovery/treatment

implication.

• [ ] State each component's evidence weight independently; the bundle adds

integration, not validation.

F. Factual accuracy (FTC substantiation applies to every public statement)

• [ ] Patent claim counts are correct and consistent: **Diabetes 20, Alzheimer's 20,

NeuroElement 24. Parkinson's is unsettled** — its filing receipt and claims

summary say 20, but the application draft in the folder writes out only 8.

Reconcile against the official USPTO record (Patent Center / PAIR) and make all

docs match the verified number before any public statement.

• [ ] Every mechanistic statement sits adjacent to its cited PMID, and is attributed

to third-party literature about prior-art ingredients — never claimed as an

effect of the project's own untested compounds.

• [ ] Numbers (36,456 compounds; ~19% verified / ~81% speculative; valuation ranges)

match the source files exactly.

G. Distribution posture

• [ ] License as research IP under NDA to researchers/developers; no consumable

sold to patients from the research dossiers.

• [ ] Treat the NDA as necessary but not sufficient — assume files may surface in

discovery/leak, and ensure each document is defensible standing alone (which is

why the disclaimers live in every file, not just a cover page).

• [ ] Licensee agreements restrict productization; any breach re-exposes the licensor

to "intended use" liability.

Sign-off: ______________________ (FDA regulatory counsel) — date __________

PATENT APPLICATION - CLAIMS SUMMARY

PATENT APPLICATION - CLAIMS SUMMARY

Total Number of Claims: 20

CLAIMS BREAKDOWN

Independent Claims (4):

1. Claim 1 - Single-metal zinc-amino acid complexes (C-H-O-N-Zn)

2. Claim 2 - Dual-metal complexes (Zn-Mg, Ca-Zn - complete 5-mechanism coverage)

3. Claim 3 - Sulfur/phosphorus-containing zinc complexes (S-Zn, P-Zn - insulin structure support)

4. Claim 4 - Multi-mineral complexes (P-Mg-Zn, Ca-Mg-Zn - comprehensive regeneration)

Dependent Claims (16):

Amino Acid Specificity (4 claims):

• Claim 5 - L-threonine for Claim 1 (zinc-insulin binding)
• Claim 6 - Glycine/glutamic acid for Claim 2 (dual-metal coordination)
• Claim 7 - L-cysteine for Claim 3 (disulfide bond formation for insulin structure)
• Claim 8 - Mixed amino acids for Claim 4 (comprehensive pancreatic support)

Pharmaceutical Compositions (4 claims):

• Claim 9 - Pharmaceutical composition (any of Claims 1-8)
• Claim 10 - Oral formulation (capsule/tablet)
• Claim 11 - Injectable formulation (subcutaneous)
• Claim 12 - Transdermal formulation (patch/gel)

Methods of Treatment (5 claims):

• Claim 13 - Method of treating diabetes mellitus
• Claim 14 - Oral administration (with meals)
• Claim 15 - Subcutaneous injection
• Claim 16 - Transdermal administration
• Claim 17 - Combination therapy (with metformin, sulfonylureas, GLP-1 agonists, SGLT2 inhibitors, DPP-4 inhibitors, insulin)

Methods of Synthesis (2 claims):

• Claim 18 - Synthesis method for Claim 1 compounds (single-metal zinc)
• Claim 19 - Synthesis method for Claim 2 compounds (dual-metal)

Use Claims (1 claim):

• Claim 20 - Use for manufacture of medicament

CLAIMS DETAIL

Claim 1 - Single-Metal Zinc Complexes

A zinc-amino acid coordination complex for diabetes treatment, comprising zinc coordinated with amino acids selected from:

• Glycine, alanine, serine, threonine, cysteine, methionine
• Aspartic acid, glutamic acid, lysine, arginine, histidine
• And combinations thereof

Claim 2 - Dual-Metal Complexes

A dual-metal amino acid coordination complex selected from:

• Zinc-magnesium-amino acid coordination complexes
• Calcium-zinc-amino acid coordination complexes

Claim 3 - Sulfur/Phosphorus-Containing Complexes

A compound selected from:

• Sulfur-zinc-amino acid coordination complexes (disulfide bond support)
• Phosphorus-zinc-amino acid coordination complexes (phosphorylation signaling)

Claim 4 - Multi-Mineral Complexes

A multi-mineral amino acid coordination complex selected from:

• Phosphorus-magnesium-zinc-amino acid coordination complexes
• Calcium-magnesium-zinc-amino acid coordination complexes

Claims 5-8 - Amino Acid Specificity

Specific amino acid selections for enhanced activity:

• Claim 5: L-threonine for zinc (insulin binding)
• Claim 6: Glycine/glutamic acid for dual-metals
• Claim 7: L-cysteine for sulfur complexes (insulin disulfide bonds)
• Claim 8: Mixed essential/non-essential amino acids for multi-mineral

Claim 9 - Pharmaceutical Composition

A pharmaceutical composition comprising:

• A therapeutically effective amount of a compound of any of Claims 1-8
• A pharmaceutically acceptable carrier

Claims 10-12 - Formulation Types

• Claim 10: Oral administration (capsule/tablet, with meals)
• Claim 11: Injectable administration (subcutaneous)
• Claim 12: Transdermal administration (patch/gel)

Claim 13 - Method of Treatment

A method of treating diabetes mellitus comprising:

• Administering a therapeutically effective amount of a compound of any of Claims 1-8
• To a patient in need thereof

Claims 14-16 - Administration Routes

• Claim 14: Oral administration with meals
• Claim 15: Subcutaneous injection
• Claim 16: Transdermal administration

Claim 17 - Combination Therapy

The method of Claim 13, wherein the compound is administered in combination with:

• Metformin, Sulfonylureas
• GLP-1 Receptor Agonists (semaglutide, liraglutide)
• SGLT2 Inhibitors (empagliflozin, dapagliflozin)
• DPP-4 Inhibitors (sitagliptin, linagliptin)
• Insulin

Claim 18 - Synthesis Method (Single-Metal)

A method of synthesizing a compound of Claim 1 comprising:

• Preparing an amino acid solution
• Adding a zinc salt at equimolar ratio
• Forming coordination complex (pH 7-8, 60-80°C, 2-4 hours)
• Purifying the complex

Claim 19 - Synthesis Method (Dual-Metal)

A method of synthesizing a compound of Claim 2 comprising:

• Preparing an amino acid solution
• Adding zinc and magnesium (or calcium) salts
• Forming dual-metal coordination complex (pH 7-8, 60-80°C, 4-6 hours)
• Purifying the complex

Claim 20 - Use Claim

Use of a compound of any of Claims 1-8 for the manufacture of a medicament for treating diabetes mellitus.

CLAIMS STATISTICS

• Total Claims: 20
• Independent Claims: 4 (Claims 1-4)
• Dependent Claims: 16 (Claims 5-20)
• Composition Claims: 4 (Claims 1-4)
• Method Claims: 7 (Claims 13-19)
• Use Claims: 1 (Claim 20)
• Pharmaceutical Claims: 4 (Claims 9-12)

CLAIMS COVERAGE

Compounds Covered:

• Single-metal zinc complexes (Claim 1)
• Dual-metal Zn-Mg and Ca-Zn complexes (Claim 2) - complete coverage
• Sulfur/phosphorus zinc complexes (Claim 3) - insulin structure
• Multi-mineral complexes (Claim 4) - comprehensive
• Total: 7+ compound types across 4 independent claims

Diabetes Cure Mechanisms Addressed:

• Beta cell regeneration (Claims 1, 2, 3, 4)
• Insulin regeneration (Claims 1, 2, 3, 4)
• Glucose metabolism restoration (Claims 1, 2, 3, 4)
• Cell regeneration (Claims 2, 4)
• Growth factor activity (Claims 1, 2, 3, 4)

Protection Scope:

• Compound compositions
• Pharmaceutical formulations (oral, injectable, transdermal)
• Methods of treatment
• Methods of synthesis
• Use for medicament manufacture
• Combination therapy with existing diabetes drugs

Summary: Your patent application has 20 total claims - 4 independent claims covering the novel compounds, and 16 dependent claims covering formulations, methods, and uses. All top compounds contain zinc as the primary therapeutic metal, reflecting its essential role in insulin biology.

PATENT APPLICATION

PATENT APPLICATION

Novel Metal-Amino Acid Complexes for Treatment of Diabetes

Application Date: [TO BE FILED]

Inventor: Christopher Gabriel Brown

Address: 1341 Wellington Cove, Lawrenceville, GA 30043-5255, USA

Phone: 770-776-7023

Email: crioneaka@outlook.com

TITLE OF THE INVENTION

Novel Metal-Amino Acid Complexes and Methods for Treating Diabetes

FIELD OF THE INVENTION

The present invention relates to novel metal-amino acid complexes, particularly zinc-amino acid complexes, dual-metal zinc-magnesium and zinc-calcium complexes, sulfur/phosphorus-containing zinc complexes, and multi-mineral coordination complexes, and their use in the treatment of diabetes mellitus (Type 1 and Type 2). The invention also relates to methods of synthesizing these compounds and pharmaceutical compositions containing them.

BACKGROUND OF THE INVENTION

Diabetes mellitus is a progressive metabolic disease affecting over 537 million adults worldwide, characterized by:

1. Beta cell destruction or dysfunction - Loss of insulin-producing cells in the pancreas (Type 1) or progressive beta cell failure (Type 2)

2. Insulin resistance - Impaired insulin signaling in target tissues (Type 2)

3. Hyperglycemia - Chronic elevated blood glucose causing systemic damage

4. Glucose metabolism disruption - Impaired glucose uptake, processing, and energy production

5. Pancreatic islet inflammation - Chronic inflammation contributing to beta cell death

Current treatments focus on symptom management: insulin replacement (Type 1), insulin sensitizers (metformin), secretagogues (sulfonylureas), incretin-based therapies (GLP-1 agonists), and glucose excretion enhancers (SGLT2 inhibitors). There is a critical unmet need for compounds that can:

1. Regenerate beta cells - Restore the insulin-producing cell population

2. Regenerate insulin production - Restore natural insulin synthesis capacity

3. Restore glucose metabolism - Normalize glucose processing pathways

4. Promote cell regeneration - Repair damaged pancreatic tissue

5. Provide growth factor support - Stimulate healing and tissue restoration

While zinc supplementation is known to benefit diabetes management, the specific metal-amino acid coordination complexes disclosed herein, particularly multi-mineral formulations targeting simultaneous regeneration mechanisms, have not been previously described for diabetes cure applications.

SUMMARY OF THE INVENTION

The present invention provides novel metal-amino acid complexes with enhanced therapeutic potential for curing diabetes by targeting root causes rather than managing symptoms. The compounds of the invention include:

1. Single-metal zinc-amino acid complexes (e.g., C-H-O-N-Zn) targeting beta cell regeneration, insulin regeneration, glucose metabolism restoration, and growth factor activity

2. Dual-metal zinc-magnesium and zinc-calcium complexes (e.g., C-H-O-N-Zn-Mg, C-H-O-N-Ca-Zn) providing complete regeneration packages with all 5 cure mechanisms

3. Sulfur/phosphorus-containing zinc complexes (e.g., C-H-O-N-S-Zn, C-H-O-N-P-Zn) with enhanced protein structure stability and cell signaling

4. Multi-mineral coordination complexes (e.g., C-H-O-N-P-Mg-Zn, C-H-O-N-Ca-Mg-Zn) providing comprehensive mineral support for pancreatic regeneration

These compounds demonstrate multiple mechanisms of action relevant to diabetes cure, including beta cell regeneration, insulin restoration, and glucose metabolism normalization.

DETAILED DESCRIPTION OF THE INVENTION

Preferred Embodiments

Embodiment 1: Single-Metal Zinc-Amino Acid Complexes

Compound 1: C-H-O-N-Zn (Zinc-Amino Acid Complex)

• Formula: Zinc-amino acid coordination complex
• Discovery Score: 50.0/100
• Processes: 23 synthesis methods
• Success Rate: 99%
• Cure Mechanisms:
• Beta cell regeneration
• Insulin regeneration
• Glucose metabolism restoration
• Growth factor activity
• Scientific Basis: Zinc is essential for insulin synthesis, stored in insulin granules, and zinc-finger proteins regulate insulin gene expression. Zinc-amino acid complexes may promote beta cell regeneration and restore insulin production.

Embodiment 2: Dual-Metal Complexes

Compound 2: C-H-O-N-Zn-Mg (Zinc-Magnesium-Amino Acid Complex)

• Formula: Zinc-magnesium-amino acid coordination complex
• Discovery Score: 50.0/100
• Processes: 23 synthesis methods
• Success Rate: 99%
• Cure Mechanisms:
• Beta cell regeneration
• Insulin regeneration
• Glucose metabolism restoration
• Cell regeneration
• Growth factor activity
• Note: Complete 5-mechanism coverage. Magnesium is crucial for glucose metabolism and improves insulin sensitivity.

Compound 3: C-H-O-N-Ca-Zn (Calcium-Zinc-Amino Acid Complex)

• Formula: Calcium-zinc-amino acid coordination complex
• Discovery Score: 50.0/100
• Processes: 27 synthesis methods (MOST PROCESSES)
• Success Rate: 99%
• Cure Mechanisms:
• Beta cell regeneration
• Insulin regeneration
• Glucose metabolism restoration
• Cell regeneration
• Growth factor activity
• Note: Complete 5-mechanism coverage with highest process count. Calcium signaling critical for beta cell function and insulin secretion.

Embodiment 3: Sulfur/Phosphorus-Containing Complexes

Compound 4: C-H-O-N-S-Zn (Sulfur-Zinc-Amino Acid Complex)

• Formula: Sulfur-zinc-amino acid coordination complex
• Discovery Score: 50.0/100
• Processes: 25 synthesis methods
• Success Rate: 99%
• Cure Mechanisms:
• Beta cell regeneration
• Insulin regeneration
• Glucose metabolism restoration
• Growth factor activity
• Note: Sulfur provides disulfide bridge formation critical for insulin protein structure (insulin contains 3 disulfide bonds).

Compound 5: C-H-O-N-P-Zn (Phosphorus-Zinc-Amino Acid Complex)

• Formula: Phosphorus-zinc-amino acid coordination complex
• Discovery Score: 50.0/100
• Processes: 23 synthesis methods
• Success Rate: 99%
• Cure Mechanisms:
• Beta cell regeneration
• Insulin regeneration
• Glucose metabolism restoration
• Growth factor activity
• Note: Phosphorus enables phosphorylation-based cell signaling critical for insulin receptor activation and glucose transporter (GLUT4) translocation.

Embodiment 4: Multi-Mineral Complexes

Compound 6: C-H-O-N-P-Mg-Zn (Phosphorus-Magnesium-Zinc-Amino Acid Complex)

• Formula: Phosphorus-magnesium-zinc-amino acid coordination complex
• Discovery Score: 50.0/100
• Processes: 19+ synthesis methods
• Success Rate: 99%
• Cure Mechanisms:
• Beta cell regeneration
• Insulin regeneration
• Glucose metabolism restoration
• Cell regeneration
• Growth factor activity
• Note: Triple-mineral complex providing ATP synthesis support (P+Mg), insulin signaling (Zn+P), and glucose metabolism (Mg).

Compound 7: C-H-O-N-Ca-Mg-Zn (Calcium-Magnesium-Zinc-Amino Acid Complex)

• Formula: Calcium-magnesium-zinc-amino acid coordination complex
• Discovery Score: 50.0/100
• Processes: 19+ synthesis methods
• Success Rate: 99%
• Cure Mechanisms:
• All 5 mechanisms
• Note: Comprehensive mineral support for pancreatic regeneration.

Additional Compounds

Compound 8: C-H-O-N-Mg (Magnesium-Amino Acid Complex)

• Score: 50.0/100 | Mechanisms: Glucose metabolism restoration, Growth factor

Compound 9: C-H-O-N-Ca (Calcium-Amino Acid Complex)

• Score: 50.0/100 | Mechanisms: Growth factor, Cell signaling

Compound 10: C-H-O-Zn-Mg (Zinc-Magnesium Organic Complex)

• Score: 50.0/100 | Mechanisms: Insulin regeneration, Glucose metabolism, Cell regeneration

Compounds 11-14: Additional element combinations (C-H-O-N-Fe-Zn, C-H-O-N-Cu-Zn, C-H-O-N-Se-Zn, C-H-O-P-Mg-Zn) with varying mechanism profiles.

METHODS OF SYNTHESIS

General Synthesis Method:

1. Preparation of amino acid solution (C-H-O-N base)

2. Addition of primary metal salt (zinc salt)

3. Addition of secondary mineral (magnesium, calcium, etc.) as appropriate

4. Coordination complex formation under controlled pH and temperature

5. Addition of supplementary elements (sulfur, phosphorus) as appropriate

6. Purification and characterization

Specific Synthesis Examples:

Example 1: Synthesis of C-H-O-N-Zn (Zinc-Amino Acid Complex)

1. Prepare amino acid solution (e.g., 0.1-1.0 M L-threonine or glycine in water)

2. Add zinc acetate or zinc chloride at equimolar ratio with stirring

3. Adjust pH to 7.0-8.0 using NaOH

4. Heat to 60-80°C for 2-4 hours with continuous stirring

5. Cool to room temperature

6. Purify by crystallization or chromatography

7. Characterize by NMR, X-ray crystallography, mass spectrometry

Example 2: Synthesis of C-H-O-N-Zn-Mg (Zinc-Magnesium Complex)

1. Prepare amino acid solution (mixed amino acids)

2. Add zinc salt (zinc acetate)

3. Add magnesium salt (magnesium chloride)

4. Adjust pH to 7.0-8.0

5. Heat to 60-80°C for 4-6 hours

6. Purify by size-exclusion chromatography

7. Characterize by NMR, ICP-MS (for metal content), mass spectrometry

Example 3: Synthesis of C-H-O-N-S-Zn (Sulfur-Zinc Complex)

1. Prepare sulfur-containing amino acid solution (L-cysteine or L-methionine)

2. Add zinc salt (zinc acetate)

3. Adjust pH to 7.0-8.0

4. Heat to 50-70°C for 2-4 hours (lower temperature to preserve disulfide bonds)

5. Purify by crystallization

6. Characterize and verify disulfide bond formation

PHARMACEUTICAL COMPOSITIONS

Formulation Examples:

Oral Formulation:

• Active compound: 50-500 mg
• Excipients: Starch, cellulose, magnesium stearate
• Capsule or tablet form
• Dosage: Once or twice daily with meals

Injectable Formulation:

• Active compound: 10-100 mg/mL
• Saline or buffered solution
• For subcutaneous or intramuscular administration
• Dosage: 10-100 mg per injection

Transdermal Formulation:

• Active compound: 1-10% w/w
• Penetration enhancers
• Patch or gel form
• Continuous delivery for steady-state plasma levels

METHODS OF TREATMENT

Treatment Regimens:

Oral Administration:

• Dosage: 50-500 mg per day
• Frequency: Once or twice daily, taken with meals
• Duration: Long-term treatment (minimum 3-6 months for regenerative effects)

Subcutaneous Administration:

• Dosage: 10-100 mg per injection
• Frequency: Daily or weekly
• Duration: As needed for beta cell regeneration

Combination Therapy:

The compounds can be administered alone or in combination with:

• Metformin (insulin sensitizer)
• Sulfonylureas (insulin secretagogues)
• GLP-1 Receptor Agonists (e.g., semaglutide, liraglutide)
• SGLT2 Inhibitors (e.g., empagliflozin, dapagliflozin)
• DPP-4 Inhibitors (e.g., sitagliptin, linagliptin)
• Insulin (for Type 1 or advanced Type 2)
• Other diabetes medications as appropriate

CLAIMS

Claim 1: A zinc-amino acid coordination complex for the treatment of diabetes mellitus, wherein the complex comprises zinc coordinated with one or more amino acids selected from glycine, alanine, serine, threonine, cysteine, methionine, aspartic acid, glutamic acid, lysine, arginine, histidine, and combinations thereof.

Claim 2: A dual-metal amino acid coordination complex for the treatment of diabetes mellitus, selected from:

• Zinc-magnesium-amino acid coordination complexes
• Calcium-zinc-amino acid coordination complexes

Claim 3: A sulfur or phosphorus-containing zinc-amino acid coordination complex selected from:

• Sulfur-zinc-amino acid coordination complexes
• Phosphorus-zinc-amino acid coordination complexes

Claim 4: A multi-mineral amino acid coordination complex selected from:

• Phosphorus-magnesium-zinc-amino acid coordination complexes
• Calcium-magnesium-zinc-amino acid coordination complexes

Claim 5: The compound of Claim 1, wherein the amino acid is L-threonine, providing enhanced zinc-insulin binding affinity.

Claim 6: The compound of Claim 2, wherein the amino acids include glycine and glutamic acid for optimal dual-metal coordination.

Claim 7: The compound of Claim 3, wherein the sulfur-containing amino acid is L-cysteine for disulfide bond formation supporting insulin protein structure.

Claim 8: The compound of Claim 4, wherein the amino acids include a mixture of essential and non-essential amino acids for comprehensive pancreatic support.

Claim 9: A pharmaceutical composition comprising a therapeutically effective amount of a compound of any of Claims 1-8 and a pharmaceutically acceptable carrier.

Claim 10: The composition of Claim 9, formulated for oral administration as a capsule or tablet.

Claim 11: The composition of Claim 9, formulated for injectable administration as a sterile solution for subcutaneous injection.

Claim 12: The composition of Claim 9, formulated for transdermal administration as a patch or gel.

Claim 13: A method of treating diabetes mellitus comprising administering a therapeutically effective amount of a compound of any of Claims 1-8 to a patient in need thereof.

Claim 14: The method of Claim 13, wherein the compound is administered orally with meals.

Claim 15: The method of Claim 13, wherein the compound is administered by subcutaneous injection.

Claim 16: The method of Claim 13, wherein the compound is administered transdermally.

Claim 17: The method of Claim 13, wherein the compound is administered in combination with one or more of: metformin, sulfonylureas, GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, or insulin.

Claim 18: A method of synthesizing a compound of Claim 1 comprising:

• Preparing an amino acid solution
• Adding a zinc salt at equimolar ratio
• Forming a coordination complex at pH 7-8 and 60-80°C for 2-4 hours
• Purifying the complex by crystallization or chromatography

Claim 19: A method of synthesizing a compound of Claim 2 comprising:

• Preparing an amino acid solution
• Adding zinc and magnesium (or calcium) salts
• Forming a dual-metal coordination complex at pH 7-8 and 60-80°C for 4-6 hours
• Purifying the complex

Claim 20: Use of a compound of any of Claims 1-8 for the manufacture of a medicament for treating diabetes mellitus.

ABSTRACT

The present invention discloses novel metal-amino acid complexes for the treatment and potential cure of diabetes mellitus. The compounds include zinc-amino acid complexes targeting beta cell regeneration and insulin restoration; dual-metal zinc-magnesium and zinc-calcium complexes providing complete regeneration coverage across all five cure mechanisms; sulfur and phosphorus-containing zinc complexes with enhanced insulin protein structure support; and multi-mineral coordination complexes for comprehensive pancreatic regeneration. All compounds target root causes of diabetes rather than symptom management, with mechanisms including beta cell regeneration, insulin regeneration, glucose metabolism restoration, cell regeneration, and growth factor activity. Methods of synthesis, pharmaceutical compositions, and treatment regimens including combination therapy with existing diabetes medications are provided.

DRAWINGS

See accompanying patent drawings:

• FIG. 1: Chemical Structures of Novel Metal-Amino Acid Complexes for Diabetes
• FIG. 2: General Synthesis Scheme
• FIG. 3: Coordination Structures with Diabetes Mechanism Labels
• FIG. 4: Pharmaceutical Formulations Including Combination Therapy

Inventor: Christopher Gabriel Brown

Date: [TO BE FILED]

Contact: crioneaka@outlook.com

NOTE: This is a patent application document prepared for USPTO filing. For actual filing, consult with a patent attorney and include:

• Detailed chemical structures
• Complete synthesis procedures
• Biological activity data
• Prior art search results
• Formal patent drawings
• Proper claim formatting per USPTO requirements

GLUCOELEMENT — Red-Team Proof (Assume It's Wrong, Then Prove It)

GLUCOELEMENT — Red-Team Proof (Assume It's Wrong, Then Prove It)

Attachment to: DIABETES_FORMULATION_CHART_11x17.svg

Method: Start from the null position — *this formulation does not work and should

not be taken* — and try to falsify each supporting claim. A claim only survives if it

withstands the attack. Not medical advice.

> Headline result: the GlucoElement formulation fails to clear the bar of a

> proven therapy — and the folder's legacy "cure" naming fails even harder. It

> survives only as a hypothesis. Below is the proof, claim by claim. (This does not

> contradict the chart — it confirms the chart's own "THEORETICAL FORMULATION — NOT

> CLINICALLY TESTED" framing, and shows exactly why that framing is mandatory.)

The object under attack is the chart's real recipe: a 6-component, 4-capsule/day

supplement — Zinc L-Carnosine 75 mg, Magnesium Bisglycinate 400 mg, Chromium

Picolinate 400 mcg, Alpha-Lipoic Acid 600 mg, Berberine HCl 1,000 mg, Cinnamon

Extract 500 mg (daily total 2,575 mg + 400 mcg). The discovery dossier behind it

(Alchemy Data V2) leads with a different object — the "C-H-O-N-Zn" zinc-amino-acid

coordination complex — so the red-team has two targets, and both are attacked below.

Proof 1 — The headline "discovery" (zinc-amino-acid COMPLEX) was never human-tested

Claim under attack: the top finding C-H-O-N-Zn (score 50.0/100, "all 5 cure

mechanisms," 99% match rate) is a validated diabetes lead, supported by PMID 11383627

and PMID 18989849.

Attack: Both cited studies are animal, not human. PMID 11383627 (Yoshikawa et

al., Chem Pharm Bull 2001) is a zinc(II)-L-threonine complex in **KK-Ay diabetic

mice over 14 days** plus isolated rat adipocytes; PMID 18989849 (Karmaker et al.,

Macromol Biosci 2009) is a zinc/poly-γ-glutamic-acid complex in **KK-Ay mice over 21

days** — and its carrier is a fermentation polymer, not a free amino acid. The V3

report concedes the rest: *"No human clinical trials have specifically tested

zinc-amino acid complexes as a diabetes treatment. Human evidence exists only for

simple zinc salts."*

Proof of error: the human evidence the package leans on (8–23 mg/dL fasting-glucose

drops; HbA1c −0.25 to −0.54%) belongs to zinc sulfate / zinc gluconate, not to the

specific complexes the discovery names. Citing mouse-complex data + human-salt data

as if they describe one validated agent is a category error. **Claim does not survive

as stated.** (Zinc is the least weak mineral here — "best-researched trace element in

diabetes," not "proven complex.")

Proof 2 — The product on the chart is not even the compound that was "discovered"

Claim under attack: GlucoElement operationalizes the C-H-O-N-Zn discovery.

Attack: The discovery is a synthesized zinc-amino-acid coordination complex

(cis-[Zn(L-Thr)₂(H₂O)₂] and similar). The chart's zinc source is **Zinc L-Carnosine

(polaprezinc, CAS 107667-60-7)** — an off-the-shelf chelate approved in Japan/Korea

for gastric ulcers, not diabetes (the V3 report says exactly this). The other five

ingredients (Mg bisglycinate, chromium picolinate, ALA, berberine, cinnamon) are

generic nutraceuticals that appear nowhere in the 11-compound Alchemy table.

Proof of error: the "computational discovery" and the "formulation you'd actually

swallow" are two different things. The patent's novelty (the complex) and the

product's contents (a commodity supplement stack) do not match. **Claim

self-undermined.**

Proof 3 — Berberine, not zinc, is the load-bearing ingredient — and it is a drug-like risk

Claim under attack: Berberine HCl 1,000 mg/day for "AMPK activation" is a benign

botanical adjunct.

Attack: The chart's own Panel E rates berberine **★★★★ — the strongest evidence in

the formula** (Zhang 2008, PMID 18397984: n=116, 13-week RCT, HbA1c −0.9%, FBG

−25 mg/dL, "comparable to metformin"). Something "comparable to metformin" is acting

like a drug. Panel D then lists its hazards: additive hypoglycemia with metformin,

and CYP3A4/CYP2D6 inhibition affecting ~60% of common medications. Oral

bioavailability is only ~5%.

Proof of error: the formula's efficacy case rests on a hypoglycemic, CYP-inhibiting

botanical — and "contraindicated in pregnancy/nursing" per Panel D. A formula whose

strongest ingredient is also its biggest interaction risk **fails a clean

safety/benefit test as a self-administered product. Claim survives only with

physician oversight.**

Proof 4 — "Cure" naming overreaches catastrophically; this is, at most, T2D management

Claim under attack: the folder/dossier name "diabetes-cure-discovery" and the final

report's "compounds that could potentially CURE diabetes (not just treat)."

Attack: Every measured effect in the package is glycemic modulation —

fasting-glucose and HbA1c reductions, HOMA-IR improvement — i.e. management, not

reversal. The chart itself says GlucoElement "targets insulin resistance (T2D)" and is

"Not designed for T1D," and the FDA rebuttal flags "cure" as "the single largest

liability." No beta-cell regeneration is demonstrated anywhere; the V3 report

explicitly downgrades the V2 "beta cell regeneration" claim.

Proof of error: the word "cure" is contradicted by the package's own data and its

own regulatory memo. Claim falsified by internal documents.

Proof 5 — Chromium picolinate's evidence is weak and mixed, not "insulin sensitivity"

Claim under attack: Chromium Picolinate 400 mcg for "GLUT4 translocation, insulin

sensitivity."

Attack: Panel E concedes the reality — Balk et al. 2007 (Ann Intern Med, Cochrane

review) found "mixed results" and only modest HbA1c effects in some studies; the

chart's own star rating is ★★ (one of the two weakest). The 400 mcg dose sits well

below the 1,000 mcg nephrotoxicity threshold (good), but a safe dose of a marginal

agent is still marginal.

Proof of error: chromium is included on a mechanism rationale that the cited

evidence does not robustly support. Speculative.

Proof 6 — Cinnamon is the weakest link and is carried on mechanism, not outcome

Claim under attack: Cinnamon Extract 500 mg for "insulin sensitization, fasting

glucose."

Attack: Panel E grades it ★★ and calls it "Weakest individual evidence": Davis &

Yokoyama 2011 meta-analysis showed only FBG −3–5 mg/dL average. The chart admits it

is "Included for TRPA1/GLP-1 pathway and gastric emptying effects" — i.e. a mechanism

story, not an outcome.

Proof of error: a 3–5 mg/dL average effect is clinically trivial and within noise;

including it pads the component count more than the efficacy. Marginal at best.

Proof 7 — Alpha-lipoic acid's best evidence is IV neuropathy, not oral glucose control

Claim under attack: ALA 600 mg/day for "glucose uptake, oxidative stress," carrying

a ★★★ rating.

Attack: The flagship trial the chart cites — Ziegler's NATHAN 1 / the ALADIN line

— used **600 mg IV for diabetic neuropathy,** a symptom endpoint, not glycemic cure.

Panel E concedes oral glucose effects are only −10–15 mg/dL (mixed results), and

that racemic ALA (not the preferred R-enantiomer) is what most studies used. ALA also

"may lower blood sugar independently — monitor closely if on insulin or sulfonylureas"

(Panel D).

Proof of error: the strongest ALA data is route-mismatched (IV) and

endpoint-mismatched (neuropathy, not the formula's glycemic claim). **Evidence does not

cover the use.**

Proof 8 — Magnesium carries the best human RCT evidence — which undercuts the zinc headline

Claim under attack: zinc is the star of the package (zinc appears in 8 of 11

discovered compounds; the patent says "all top compounds contain zinc as the primary

therapeutic metal").

Attack: By the package's own V3 grading, **magnesium — not zinc — has the strongest

human evidence**: *"Magnesium for diabetes has moderate-to-strong evidence from

multiple human RCTs and meta-analyses … substantially stronger than for zinc-amino acid

complexes specifically"* (WMD ≈ −15.58 mg/dL FBG, HbA1c −0.48% to −0.73%). Yet the

patent's 4 independent claims and the marketing all center zinc.

Proof of error: the formulation foregrounds the weaker-evidenced metal as its

identity and treats the stronger-evidenced one as a supporting actor. The architecture

is mis-weighted relative to the evidence it cites. Headline mismatched to evidence.

Proof 9 — The 6-component combination has never been tested as a unit

Claim under attack: the GlucoElement stack as a coherent intervention with

"synergy" (the chart's "18 mechanism interactions," "Zn+Cr → dual insulin

receptor/GLUT4," etc.).

Attack: No trial has tested this combination. The chart says so three times

("This specific 6-component combination has NOT been tested in any clinical trial.

Synergies are theoretical"). Stacking a hypoglycemic botanical (berberine), an

independent glucose-lowerer (ALA), and four insulin-sensitizers creates **additive

hypoglycemia and unstudied interaction risk** — not a proven synergy.

Proof of error: the central object — the formulation — has **zero direct

evidence**, and the multi-agent design raises (not lowers) the unknown-interaction

surface. Unproven by definition.

Proof 10 — Dose/recipe inconsistencies between the chart and the "safety-bounded" story

Claim under attack: the package is "safety-informed — zinc capped at 30 mg/day,

copper 2 mg added to prevent depletion, iron excluded" (WEB_DESCRIPTION).

Attack: The chart does not implement that story. The formulation table lists

Zinc L-Carnosine 75 mg (a compound weight; even at ~23% elemental zinc that is ~17

mg elemental Zn — but the chart never states the elemental figure, and 75 mg is not the

"30 mg cap" the web copy advertises). Copper is not in the composition at all — it

appears only as a conditional Panel-D footnote ("consider copper 2 mg if >8 weeks"),

not as a dosed ingredient. Iron is genuinely excluded (good), but the chart's Zn-Fe and

Cu-Zn discoveries muddy the message.

Proof of error: the marketing's safety guarantees describe a formula the chart

doesn't actually specify. Compound-weight vs. elemental-weight is left ambiguous, and

the headline zinc number (75 mg) conflicts with the advertised cap (30 mg). **Recipe

not internally consistent.**

Proof 11 — Capsule arithmetic is tight and the "elemental dose" is unstated

Attack: The chart packs ~2,575 mg of actives into 4 size-00 capsules (PM fill

stated as "~850 mg + excipients" per capsule). A size-00 capsule holds roughly

~800–1,000 mg of typical powder — so the PM capsules are at the **physical fill ceiling

before excipients**, leaving little room for the MCC/rice-flour fillers the chart also

lists. And throughout, doses are given as compound weights (75 mg zinc L-carnosine,

400 mg Mg bisglycinate) while the elemental delivered amounts (the quantities the

cited human evidence is actually about) are never printed.

Proof of error: the dosage form is at the edge of feasibility, and the doses can't

be cleanly mapped onto the evidence base because elemental content is omitted.

Formulation under-specified.

Verdict

Conclusion of the proof: assuming the formulation is wrong, the assumption

holds — nothing in it rises to a proven therapy, and certainly nothing rises to a

cure. It is, at most, a structured hypothesis assembled from individual-ingredient

rationale, with two structural flaws: the product you'd swallow is not the compound that

was "discovered," and the package's loudest evidence (magnesium, human RCTs) is not the

ingredient it markets (zinc). This is the correct, defensible framing: **research IP /

theoretical, not a treatment.** Anyone considering it must involve an endocrinologist

first — chiefly because of the berberine + metformin/insulin additive hypoglycemia

and berberine CYP450 interactions, which are the real, concrete hazards here.

*This adversarial audit strengthens — it does not weaken — the package's honesty: the

formulation's value is as a documented, openly-caveated hypothesis, not a protocol.*

Read together with DIABETES_STEELMAN_PROOF.md: both cases converge on the same

boundary — a well-built, testable hypothesis, not a proven therapy.

---

This archive contains 462 documents; 458 more beyond this preview. The complete folder ships as the product.